Rankings
▼
Calendar
FENC (Fennec Pharmaceuticals Inc.) Stock Financials & Earnings | Market Cap Arena
FENC
Fennec Pharmaceuticals Inc.
Mkt Cap
$220M
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$39M
Net Income (TTM)
-$7M
EPS (TTM)
-$0.24
Free Cash Flow (TTM)
-$8M
Gross Margin
93.1%
Op. Margin
-12.0%
Net Margin
-17.9%
FCF Margin
-20.6%
P/S Ratio (TTM)
5.7x
P/E Ratio (TTM)
—
YoY Rev Growth
-21.8%
Employees
—
Earnings Reports
▶
Q3 2025
Browse All Reports
Next: Q4 2025 · Apr 1
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q4 22
$2M
$1M
-$6M
Q1 23
$2M
$2M
-$5M
Q2 23
$3M
$3M
-$5M
Q3 23
$7M
$6M
-$1M
Q4 23
$10M
$9M
-$2M
Q1 24
$25M
$25M
$14M
Q2 24
$7M
$7M
-$5M
Q3 24
$7M
$6M
-$5M
Q4 24
$8M
$7M
-$934K
Q1 25
$9M
$8M
-$808K
Q2 25
$10M
$9M
-$3M
Q3 25
$12M
$12M
-$189K
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q4 22
143.5x
—
Q1 23
68.6x
—
Q2 23
33.5x
—
Q3 23
16.8x
—
Q4 23
10.2x
—
Q1 24
4.9x
81.6x
Q2 24
4.5x
82.8x
Q3 24
4.4x
—
Q4 24
4.6x
—
Q1 25
7.1x
—
Q2 25
6.6x
—
Q3 25
5.7x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q4 22
-$7M
-$7M
Q1 23
-$6M
-$6M
Q2 23
-$4M
-$4M
Q3 23
-$3M
-$3M
Q4 23
-$5M
-$5M
Q1 24
$39M
$39M
Q2 24
-$8M
-$8M
Q3 24
-$2M
-$2M
Q4 24
-$1M
-$1M
Q1 25
-$4M
-$4M
Q2 25
-$4M
-$4M
Q3 25
$1M
$1M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q4 22
—
+82.9%
Q1 23
—
+93.2%
Q2 23
—
+62.8%
Q3 23
—
+0.2%
Q4 23
+551.7%
+54.8%
Q1 24
+1413.2%
+67.5%
Q2 24
+115.6%
+51.9%
Q3 24
+7.0%
+61.7%
Q4 24
-20.8%
-25.4%
Q1 25
-65.5%
-17.8%
Q2 25
+32.9%
+0.7%
Q3 25
+78.7%
+3.9%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q4 22
$857K
55.8%
Q1 23
$1M
64.9%
Q2 23
$3M
75.5%
Q3 23
$865K
13.3%
Q4 23
$857K
8.6%
Q1 24
$1M
4.7%
Q2 24
$925K
12.7%
Q3 24
$2M
26.1%
Q4 24
$1M
14.2%
Q1 25
$798K
9.1%
Q2 25
$1M
15.5%
Q3 25
$2M
17.8%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q4 22
$117K
$5M
$3M
—
Q1 23
$4K
$4M
$3M
—
Q2 23
$8K
—
—
$8M
Q3 23
$12K
$4M
$3M
—
Q4 23
$33K
—
—
$11M
Q1 24
$3K
$6M
$5M
—
Q2 24
$157K
$7M
$5M
—
Q3 24
$97K
$6M
$5M
—
Q4 24
$50K
$4M
$4M
—
Q1 25
$94K
$6M
$3M
—
Q2 25
$107K
$7M
$4M
—
Q3 25
$29K
$7M
$5M
—
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q4 22
$24M
$0
$24M
Q1 23
$18M
$0
$18M
Q2 23
$15M
$0
$15M
Q3 23
$12M
$0
$12M
Q4 23
$13M
$0
$13M
Q1 24
$51M
$0
$51M
Q2 24
$43M
$0
$43M
Q3 24
$40M
$0
$40M
Q4 24
$27M
$0
$27M
Q1 25
$23M
$0
$23M
Q2 25
$19M
$0
$19M
Q3 25
$22M
$0
$22M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q4 22
26M
+1.0%
Q1 23
27M
+0.8%
Q2 23
26M
-0.4%
Q3 23
26M
+0.0%
Q4 23
27M
+1.4%
Q1 24
31M
+15.9%
Q2 24
27M
-12.2%
Q3 24
27M
+0.3%
Q4 24
27M
+0.3%
Q1 25
28M
+0.4%
Q2 25
28M
+0.3%
Q3 25
28M
+0.8%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 13
$0
1
FY 14
$0
1
FY 15
$0
3
FY 16
$0
3
FY 17
$0
3
FY 18
$0
3
FY 19
$0
4
FY 20
$19K
9
FY 21
$0
10
FY 22
$41K
36
FY 23
$733K
29
FY 24
$1M
32
marketcaparena.com